Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock

Now watching

Next video starts in : 7 Play

Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock

Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock
Replay video
Up next

Jim Cramer Explains Why Panera and Thermo Fisher Are Both Buys

Unlock your personal NFL Now stream by signing in to NFL.com

Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock

by TheStreet 2:50 mins

Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock

by TheStreet 2:50 mins

The recent volatility surrounding Radius Health shares should lessen as the market starts focusing on its osteoporosis drug Abaloparatide, said the company's CEO Robert Ward. Radius Health sold 6.5 million shares of stock $8 a share in a June IPO, raising $52 million. Abaloparatide is in Phase III development and has exhibited faster improvement in bone mineral density at all sites in a pair of confirmatory Phase II studies. Ward said he expects the pivotal trial readout in December and hopes to submit and NDA in mid-2015. Ward said the company has not partnered with a larger drug company yet, and has raised more than enough money to get Abaloparatide to market.

TheStreet

Market Movers

  1. 14:30

    Nasdaq set to top record; Apple Watch deliveries; Comcast abandons merger

  2. 2:38

    Cablevision to offer 'cord cutters' package

  3. 3:40

    Comcast abandons Time Warner Cable merger

  4. 1:24

    Chipotle begins delivery

  5. 2:06

    Amazon hits new high; Google, Microsoft and Starbucks zoom higher

  6. 11:31

    Big earnings day; Facebook investors 'unlike'; cable merger woes